Call for Public Review: Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment

Call for Public Review:
Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

and

ECG-based Signal Analysis Technologies
---------------
The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment (TA) Program develops systematic reviews, health technology assessments, and other reports at the request of the Centers for Medicare & Medicaid Services (CMS) Coverage and Analysis Group. These reports are funded by an Interagency Agreement from CMS to AHRQ and used to inform national coverage policies, discussion at public Medicare Evidence Development and Coverage Advisory Committee (MedCAC) meetings, and/or for other policy considerations.

To get complete public review, the AHRQ TA Program will post draft reports on the AHRQ TA Web site. To meet the timelines for Medicare coverage decisions mandated by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, draft technology assessment reports will be available for public review for a limited time. A notice will be sent out on the CMS Medicare Coverage and AHRQ Effective Health Care E-mail distribution lists 1 week before the posting of draft reports. Each report will be available for public review on this Web site for a total of 2 weeks.

AHRQ's TA Program supports and is committed to the transparency of its review process. Therefore, starting March 18, 2009, invited peer review comments and public review comments will be publicly posted on the TA Program Web site at http://www.ahrq.gov/clinic/techix.htm within 3 months after the associated final report is posted on this Web site. The report authors' responses to the comments (the "disposition of comments") will be posted on the same Web page as the associated comments.


--------------
Review Steps
When a draft Technology Assessment report is available for review, you may review the draft report by completing the associated review form and then selecting "Submit" on the form.

Note: Comments received after the review period will not be accepted.

.Currently Available for Review
..Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (Draft Report, PDF file, 3.4 MB; PDF Help; 185 pages)
http://www.ahrq.gov/clinic/ta/pharmgentest.pdf

Date Available: 9:00 AM, January 27, 2010, to 5:00 PM, February 10, 2010


ECG-based Signal Analysis Technologies (Draft Report, PDF file, 625 KB; PDF Help; 97 pages)
Date Available: 9:00 AM, January 12, 2010, to 5:00 PM, January 27, 2010
http://www.ahrq.gov/clinic/ta/ecg-based-sat.pdf


Persons with disabilities experiencing problems accessing portions of the PDF files for draft reports should contact the Technology Assessment Program at ahrqtap@ahrq.hhs.gov.

If you have any problems with your submission, please E-mail your comments along with a statement indicating your acceptance of the AHRQ Technology Assessment Program Public Review disclosure policy to tareview@ahrq.hhs.gov. Thank you.

Questions

Please contact ahrqtap@ahrq.hhs.gov if you have any questions.

Current as of January 2010


------------------
Internet Citation:

Call for Public Review. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/ta/tareview.htm

abrir aquí para acceder al documento AHRQ general:
Call for Public Review